Cognition Therapeutics, Inc. (CGTX)
Company Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.
The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial.
Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration.
The company was incorporated in 2007 and is headquartered in Purchase, New York.
Country | United States |
Founded | 2007 |
IPO Date | Oct 8, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 22 |
CEO | Ms. Lisa Ricciardi |
Contact Details
Address: 2403 Sidney Street, Suite 261 Pittsburgh, Pennsylvania 15203 United States | |
Phone | 412-481-2210 |
Website | cogrx.com |
Stock Details
Ticker Symbol | CGTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $12.00 |
CIK Code | 0001455365 |
CUSIP Number | 19243B102 |
ISIN Number | US19243B1026 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Lisa Ricciardi | Chief Executive Officer, President and Director |
Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of Research & Development |
John Brendan Doyle | Chief Financial Officer |
Dr. Steven A. Weissman Ph.D. | Vice President and Head of CMC |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 26, 2024 | 10-K | Annual Report |
Mar 26, 2024 | 8-K | Current Report |
Mar 13, 2024 | 8-K | Current Report |
Mar 13, 2024 | 424B5 | Filing |
Mar 11, 2024 | 8-K | Current Report |
Mar 11, 2024 | 424B5 | Filing |
Feb 20, 2024 | 8-K | Current Report |
Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |